Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02335060 · ClinicalTrials.gov registry record · Early Phase 1
N-acetylcysteine Effects on Tetrahydrocannabinol
A Early Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT02335060 is a Early Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 5 participants.
The verdict
NCT02335060, a Early Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The overall purpose of this study is to examine the effect of N-acetylcysteine (NAC) on the acute effects of Delta-9-tetrahydrocannabinol (THC). This will be tested by pretreating healthy individuals with NAC and then assessing their responses to THC.
Interventions
- DRUG Placebo
- DRUG N-acetylcysteine
- DRUG Delta-9-THC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2014-05-02 |
| Est. Completion | 2014-09-16 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02335060
The ClinicalTrials.gov registry entry for NCT02335060 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02335060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02335060 about?
NCT02335060 is a clinical study titled "N-acetylcysteine Effects on Tetrahydrocannabinol". The overall purpose of this study is to examine the effect of N-acetylcysteine (NAC) on the acute effects of Delta-9-tetrahydrocannabinol (THC). This will be tested by pretreating healthy individuals with NAC and then assessing their responses to THC.
What is the current status of trial NCT02335060?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2014-05-02. Estimated completion is 2014-09-16.
What interventions are being tested in trial NCT02335060?
The interventions under investigation include: Placebo (DRUG), N-acetylcysteine (DRUG), Delta-9-THC (DRUG).
Who is sponsoring clinical trial NCT02335060?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.